Want to see SG:P8A full AI Analyst Report?
Top Page
Cordlife Group
(SGX:P8A)
Select Model
Select Model
Rating:44Neutral
Price Target:
S$0.15
▲(15.38% Upside)
Action:Reiterated
Date:07/04/26
The score is driven primarily by weak financial performance—deep losses and negative cash flow—partly offset by a conservatively levered balance sheet. Technical indicators (negative MACD, low RSI and stochastic) reinforce a cautious near-term view. Valuation is difficult to assess positively because the negative P/E reflects current unprofitability, and no dividend yield data is available.
Positive Factors
Conservative balance sheet
Very low leverage (debt-to-equity ~0.04) gives durable financial flexibility, allowing the company to absorb near-term losses, fund restructuring or targeted investments without immediate refinancing pressure. That cushion supports operational continuity across 2–6 months while turnaround actions are implemented.
Negative Factors
Deep operating losses
Sustained negative EBIT (~-37%) and net margins (~-32%) show the company is burning operating profit at scale. Such large structural losses require substantive cost reduction or material revenue expansion to correct, and they meaningfully weaken the firm's ability to reinvest and achieve durable profitability within several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage (debt-to-equity ~0.04) gives durable financial flexibility, allowing the company to absorb near-term losses, fund restructuring or targeted investments without immediate refinancing pressure. That cushion supports operational continuity across 2–6 months while turnaround actions are implemented.
Read all positive factors
Cordlife Group (P8A) vs. iShares MSCI Singapore ETF (EWS)
Market Cap
S$39.57M
Dividend YieldN/A
Average Volume (3M)14.19K
Price to Earnings (P/E)―
Beta (1Y)0.06
Revenue GrowthN/A
EPS GrowthN/A
CountrySG
Employees596
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.05
Shares Outstanding267,525,360
10 Day Avg. Volume3,230
30 Day Avg. Volume14,193
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.32
Price to Sales (P/S)0.86
P/FCF Ratio-45.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cordlife Group Business Overview & Revenue Model
Company Description
Established in Singapore in 2001, Cordlife Group Limited functions as an investment holding company, delivering cord blood banking solutions across a global footprint that includes Singapore, Hong Kong, India, Malaysia, and the Philippines. Its op...
How the Company Makes Money
Cordlife primarily makes money through fees associated with its cell banking services. The core revenue stream is collecting umbilical cord blood and/or cord tissue at birth, processing and testing these samples in its laboratories, and storing th...
Cordlife Group Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 36.20M | 38.85M | 27.84M | 55.73M | 55.16M | 56.67M |
| Gross Profit | 20.51M | 21.75M | 11.73M | 37.30M | 37.19M | 39.48M |
| EBITDA | -9.58M | -10.74M | -14.38M | 8.56M | 9.34M | 10.78M |
| Net Income | -11.57M | -12.64M | -18.69M | 3.52M | 4.89M | 6.13M |
Balance Sheet | ||||||
| Total Assets | 200.48M | 201.76M | 217.14M | 228.46M | 228.00M | 233.71M |
| Cash, Cash Equivalents and Short-Term Investments | 45.33M | 51.70M | 60.58M | 65.01M | 65.17M | 64.63M |
| Total Debt | 4.39M | 1.34M | 2.42M | 3.50M | 2.22M | 2.97M |
| Total Liabilities | 98.09M | 97.28M | 98.68M | 92.81M | 93.67M | 97.02M |
| Stockholders Equity | 102.21M | 104.30M | 118.21M | 135.33M | 134.06M | 136.43M |
Cash Flow | ||||||
| Free Cash Flow | -1.85M | -729.00K | -15.62M | 6.96M | 5.32M | 7.93M |
| Operating Cash Flow | -820.41K | 504.00K | -11.31M | 9.80M | 7.71M | 9.50M |
| Investing Cash Flow | 12.67M | 2.77M | -2.81M | -2.63M | 4.43M | -23.91M |
| Financing Cash Flow | -2.52M | -2.10M | 7.17M | -1.86M | -13.45M | 3.37M |
Cordlife Group Technical Analysis
Positive
0.13
Price Trends
0.14
Positive
0.14
Positive
0.15
Positive
Market Momentum
<0.01
Negative
85.84
Negative
35.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:P8A, the sentiment is Positive. The current price of 0.13 is above the 20-day moving average (MA) of 0.13, below the 50-day MA of 0.14, and below the 200-day MA of 0.15, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 85.84 is Negative, neither overbought nor oversold. The STOCH value of 35.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:P8A.
Cordlife Group Peers Comparison
UnderperformOutperform
Sector (51)
SG:P8A
Cordlife Group
0.16
-0.13
-44.64%
SG:BSL
Raffles Medical Group
0.93
-0.05
-5.01%
SG:A50
Thomson Medical Group Ltd.
0.05
0.01
23.26%
SG:40T
ISEC Healthcare Ltd
0.32
-0.02
-6.80%
SG:5WA
OUE Lippo Healthcare Limited
0.04
0.02
69.57%
SG:TBDD
Bangkok Dusit Medical Services Public Co Ltd Shs UnSp Singapore Depositary Receipt Repr 2/1 Sh
1.48
-0.07
-4.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.